D’Anna, Lucio http://orcid.org/0000-0002-6794-3850
Romoli, Michele
Harvey, Kirsten
Korompoki, Eleni
Veltkamp, Roland
Funding for this research was provided by:
Bristol-Myers Squibb
Pfizer
Article History
Received: 27 June 2024
Revised: 25 August 2024
Accepted: 27 August 2024
First Online: 31 August 2024
Declarations
:
: Lucio D’Anna and Kirsten Harvey report no disclosures. Eleni Korompoki: Speaker Honoraria: Amgen, INNOVIS, Pfizer; Advisory boards: Pfizer. Roland Veltkamp has received fees for consulting and speaker honoraria from Astra Zeneca, Bayer, BMS, Pfizer, as well as research support from Bayer, Boehringer, BMS, Pfizer, Daiichi Sankyo, Medtronic, outside of the present work.
: The EIDASAF study was approved by the Health Research Authority for collection of data within the NHS. The research did not require review by the UK Health Departments Research Ethics Service as it fell into the category of ‘Research limited to use of previously collected, non-identifiable information.’ Informed consent was not a legal requirement as the research was carried out using data collected as part of routine care and any researchers outside of the direct care team only had access to anonymised data.